Trial results due soon, expecting interim phase 2 data which is a pretty big deal in itself.
Company has been working with the FDA to nut out a short phase 2b trial (starting 2017) and short phase 3 trial thereafter. Seeming undervalued for a biotech in phase 2?
However, their more valuable asset is the discovery platform they own which has the potential to shake up the biotech world in a way that changes how drugs are discovered - across many areas of unmet clinical need.
Check out a few recent news articles posted on Dimerix, their recent announcements and a few posts on this forum too.
Very exciting stock right now, especially for the long termers here.
DXB Chart ready to move, page-3
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.020(4.65%) |
Mkt cap ! $247.7M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 46.3¢ | 42.5¢ | $1.449M | 3.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 143129 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 73280 | 3 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |